Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last3,781 to 3,800 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Standard Breast Irradiation vs Breast Radiation Plus Regional Radiation: serious adverse events | 1 of 927 3 of 893 | -0.2 points -0.9 to 0.3 | 1,820 | NCT00005957 Radiation Therapy in Treating Women Who Have Undergone Surgery for Early-Stage Invasive Breast Cancer |
| Standard of Care Plus (SCP) vs Collaborative Care/Stepped Care (CC/SC): deaths from any cause | 21 of 927 34 of 893 | -1.5 points -3.2 to 0.0 | 1,820 | NCT02674464 Reducing Inequities in Care of Hypertension, Lifestyle Improvement for Everyone (RICH LIFE Project) |
| AAC Only vs AAC + TMCP: Number of Patients Contacted for Quitline Enrollment | 273 of 1,393 59 of 426 | 5.7 points 1.6 to 9.4 | 1,819 | NCT02764385 Using a Teachable Moment Communication Process to Improve Outcomes of Quitline Referrals |
| EVO100 Gel vs Placebo Gel: Percentage of Study Successes in the EVO100 and Placebo Treatment Groups | 684 of 906 696 of 913 | -0.7 points -4.7 to 3.2 | 1,819 | NCT04553068 Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection |
| All TNFI Initiators Monotherapy vs Tofacitinib Initiators Monotherapy: Number of Participants With mACR20 at 6 Months for Tofacitinib Monotherapy vs TNFi Monotherapy | 394 of 1,683 28 of 135 | 2.7 points -5.2 to 9.0 | 1,818 | NCT05576051 To Estimate the Efficacy of Treatment With TNFi as Monotherapy or Combination Therapy With MTX and Compare and Contrast Efficacy With Tofacitinib as Monotherapy and Combination Therapy in a Real World Setting. |
| Nirsevimab vs No Intervention: Number of Participants With Recurrent Wheeze (for United Kingdom Reconsented Participants) | 101 of 928 96 of 888 | 0.1 points -2.8 to 2.9 | 1,816 | NCT05437510 Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life |
| Olaparib vs Placebo: serious adverse events | 79 of 911 79 of 904 | -0.1 points -2.7 to 2.5 | 1,815 | NCT02032823 Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer |
| Non-Opioid vs Opioid: Number of Participants Receiving Rescue Medication | 26 of 909 54 of 906 | -3.1 points -5.1 to -1.2 | 1,815 | NCT04452344 Opioid Analgesic Reduction Study |
| Non-Opioid vs Opioid: serious adverse events | 1 of 909 2 of 906 | -0.1 points -0.7 to 0.4 | 1,815 | NCT04452344 Opioid Analgesic Reduction Study |
| High Tranfusion Threshold vs Low Transfusion Threshold: serious adverse events | 206 of 908 197 of 906 | 0.9 points -2.9 to 4.8 | 1,814 | NCT01702805 Transfusion of Prematures Trial |
| Dalteparin vs Placebo: Number of Participants With Minor Bleeding | 187 of 895 110 of 918 | 8.9 points 5.5 to 12.3 | 1,813 | NCT00786474 Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study) |
| Dalteparin vs Placebo: Major Bleeding | 29 of 895 12 of 918 | 1.9 points 0.6 to 3.4 | 1,813 | NCT00786474 Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study) |
| Absorb BVS vs XIENCE: Landmark Analysis on TLF and Components | 38 of 1,202 16 of 610 | 0.5 points -1.3 to 2.1 | 1,812 | NCT01751906 ABSORB III Randomized Controlled Trial (RCT) |
| RV Pacing vs Biventricular Pacing: Chronic Atrial Fibrillation (Defined as Presence of Atrial Fibrillation in Two Subsequent ECG´s/Visits) | 91 of 908 76 of 902 | 1.6 points -1.1 to 4.3 | 1,810 | NCT00187278 Biopace Study: Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization |
| RV Pacing vs Biventricular Pacing: Total Mortality | 307 of 908 305 of 902 | -0.0 points -4.4 to 4.3 | 1,810 | NCT00187278 Biopace Study: Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization |
| RV Pacing vs Biventricular Pacing: Adverse Events Related to Left Ventricular Lead | 1 of 908 38 of 902 | -4.1 points -5.6 to -2.9 | 1,810 | NCT00187278 Biopace Study: Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization |
| RV Pacing vs Biventricular Pacing: Death Due to Cardiovascular Causes | 106 of 908 107 of 902 | -0.2 points -3.2 to 2.8 | 1,810 | NCT00187278 Biopace Study: Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization |
| RV Pacing vs Biventricular Pacing: Death or Heart Failure Hospitalization | 346 of 908 363 of 902 | -2.1 points -6.6 to 2.4 | 1,810 | NCT00187278 Biopace Study: Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization |
| RV Pacing vs Biventricular Pacing: deaths from any cause | 307 of 908 305 of 902 | -0.0 points -4.4 to 4.3 | 1,810 | NCT00187278 Biopace Study: Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization |
| RV Pacing vs Biventricular Pacing: serious adverse events | 641 of 908 698 of 902 | -6.8 points -10.8 to -2.7 | 1,810 | NCT00187278 Biopace Study: Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization |
Code
curl "https://conductscience.org/api/comparisons/v1?page=190"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=190
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00005957-sae",
"title": "Standard Breast Irradiation vs Breast Radiation Plus Regional Radiation: serious adverse events",
"summary": "1 of 927 against 3 of 893; risk difference -0.2 points, 95% interval -0.9 to 0.3; NCT00005957, Radiation Therapy in Treating Women Who Have Undergone Surgery for Early-Stage Invasive Breast Cancer",
"record": "/library/comparisons/NCT00005957-sae",
"nct_id": "NCT00005957",
"kind": "serious-adverse-events",
"participants": 1820,
"risk_difference": {
"value": -0.002280713834438054,
"lower": -0.008812239734750147,
"upper": 0.0031941949991347893
},
"group_1": "1 of 927",
"group_2": "3 of 893",
"difference": "-0.2 points",
"interval": "-0.9 to 0.3",
"trial_title": "Radiation Therapy in Treating Women Who Have Undergone Surgery for Early-Stage Invasive Breast Cancer"
},
{
"id": "NCT02674464-deaths",
"title": "Standard of Care Plus (SCP) vs Collaborative Care/Stepped Care (CC/SC): deaths from any cause",
"summary": "21 of 927 against 34 of 893; risk difference -1.5 points, 95% interval -3.2 to 0.0; NCT02674464, Reducing Inequities in Care of Hypertension, Lifestyle Improvement for Everyone (RICH LIFE Project)",
"record": "/library/comparisons/NCT02674464-deaths",
"nct_id": "NCT02674464",
"kind": "deaths",
"participants": 1820,
"risk_difference": {
"value": -0.015420186491844151,
"lower": -0.0320202154543638,
"upper": 0.0004577838311548531
},
"group_1": "21 of 927",
"group_2": "34 of 893",
"difference": "-1.5 points",
"interval": "-3.2 to 0.0",
"trial_title": "Reducing Inequities in Care of Hypertension, Lifestyle Improvement for Everyone (RICH LIFE Project)"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=191",
"request_id": "TPVFMvB42G7tRUJE"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant